Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DermTech, Inc.DMTK · Entity 89998 | Chief Commercial Officer | June 12, 2023 | June 14, 2023 |
| Vyome Holdings, IncOBLN · Entity 1824 | Vice President of Sales | August 23, 2018 | August 27, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DermTech, Inc.
Report date June 12, 2023 · Filed June 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 284,757 |
Reported balance
After 2023-06-12 transaction · row 1
1 source rowRow 1 · 2023-06-12 · Sale · Disposed 350 · Balance 284,757 F1: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on June 24, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on June 24, 2020.
Vyome Holdings, Inc
Report date August 23, 2018 · Filed August 27, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,494 |
Reported balance
After 2018-08-23 transaction · row 1
1 source rowRow 1 · 2018-08-23 · Grant · Acquired 5,494 · Balance 5,494 F1: The reporting person purchased these shares directly from the issuer in a private placement. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person purchased these shares directly from the issuer in a private placement.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALIMERA SCIENCES INC
Report date September 16, 2024 · Filed September 18, 2024
Section 16 reporting ended · disclosed 2024-09-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-09-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-09-16 · Disposition to issuer · Disposed 125,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of June 21, 2024 (the "Merger Agreement"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation ("Parent") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the "Effective Time"), each restricted stock unit (each, an "RSU") granted by the Issuer that was outstanding and unvested immediately prior to the Effective Time was converted into the right to receive (i) an amount of cash equal to the product of (A) the number of shares of common stock then underlying such RSU multiplied by (B) $5.50 in cash, without interest (such amount, the "Closing Cash Consideration") and (ii) contingent value rights ("CVRs") in an amount equal to the total number of shares of common stock then underlying such RSUs. |
| Performance-Based Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-09-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-09-16 · Disposition to issuer · Disposed 125,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, as of the Effective Time, each performance-based restricted stock unit (each, an "PSU") granted by the Issuer that was outstanding and unvested immediately prior to the Effective Time was converted into the right to receive (i) an amount of cash equal to the product of (A) the number of shares of common stock then underlying such PSU multiplied by (B) the Closing Cash Consideration and (ii) CVRs in an amount equal to the total number of shares of common stock then underlying such PSUs. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.71 · Expires 2027-12-11 | Direct | 0 |
Reported balance
After 2024-09-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-09-16 · Disposition to issuer · Disposed 125,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an "Option") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than the Closing Cash Consideration was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to: (A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one CVR. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of June 21, 2024 (the "Merger Agreement"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation ("Parent") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the "Effective Time"), each restricted stock unit (each, an "RSU") granted by the Issuer that was outstanding and unvested immediately prior to the Effective Time was converted into the right to receive (i) an amount of cash equal to the product of (A) the number of shares of common stock then underlying such RSU multiplied by (B) $5.50 in cash, without interest (such amount, the "Closing Cash Consideration") and (ii) contingent value rights ("CVRs") in an amount equal to the total number of shares of common stock then underlying such RSUs.
F2: Pursuant to the terms of the Merger Agreement, as of the Effective Time, each performance-based restricted stock unit (each, an "PSU") granted by the Issuer that was outstanding and unvested immediately prior to the Effective Time was converted into the right to receive (i) an amount of cash equal to the product of (A) the number of shares of common stock then underlying such PSU multiplied by (B) the Closing Cash Consideration and (ii) CVRs in an amount equal to the total number of shares of common stock then underlying such PSUs.
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an "Option") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than the Closing Cash Consideration was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to: (A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one CVR.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2024 Filed Sep 18, 2024 21:53 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | Disposition to issuerStock Option (Right to Buy) · Derivative | 125,000 | Not disclosed Strike: $3.71 | Not disclosed |
DisclosureSEC source: 0001104659-24-101110 · tm2424353-12_4seq1.xml · derivative · entry 3 Wood Todd Michael · CIK 0001739840 · President of U.S. Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2027-12-11 F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an "Option") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than the Closing Cash Consideration was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to: (A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one CVR. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an "Option") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than the Closing Cash Consideration was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to: (A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one CVR. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 21:53 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | Disposition to issuerPerformance-Based Restricted Stock Units · Derivative | 125,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-101110 · tm2424353-12_4seq1.xml · derivative · entry 2 Wood Todd Michael · CIK 0001739840 · President of U.S. Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires not disclosed F2 · derivative.exercise_price: Pursuant to the terms of the Merger Agreement, as of the Effective Time, each performance-based restricted stock unit (each, an "PSU") granted by the Issuer that was outstanding and unvested immediately prior to the Effective Time was converted into the right to receive (i) an amount of cash equal to the product of (A) the number of shares of common stock then underlying such PSU multiplied by (B) the Closing Cash Consideration and (ii) CVRs in an amount equal to the total number of shares of common stock then underlying such PSUs. F2 · price: Pursuant to the terms of the Merger Agreement, as of the Effective Time, each performance-based restricted stock unit (each, an "PSU") granted by the Issuer that was outstanding and unvested immediately prior to the Effective Time was converted into the right to receive (i) an amount of cash equal to the product of (A) the number of shares of common stock then underlying such PSU multiplied by (B) the Closing Cash Consideration and (ii) CVRs in an amount equal to the total number of shares of common stock then underlying such PSUs. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, as of the Effective Time, each performance-based restricted stock unit (each, an "PSU") granted by the Issuer that was outstanding and unvested immediately prior to the Effective Time was converted into the right to receive (i) an amount of cash equal to the product of (A) the number of shares of common stock then underlying such PSU multiplied by (B) the Closing Cash Consideration and (ii) CVRs in an amount equal to the total number of shares of common stock then underlying such PSUs. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, as of the Effective Time, each performance-based restricted stock unit (each, an "PSU") granted by the Issuer that was outstanding and unvested immediately prior to the Effective Time was converted into the right to receive (i) an amount of cash equal to the product of (A) the number of shares of common stock then underlying such PSU multiplied by (B) the Closing Cash Consideration and (ii) CVRs in an amount equal to the total number of shares of common stock then underlying such PSUs. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 21:53 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | Disposition to issuerRestricted Stock Units · Derivative | 125,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-101110 · tm2424353-12_4seq1.xml · derivative · entry 1 Wood Todd Michael · CIK 0001739840 · President of U.S. Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires not disclosed F1 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger, dated as of June 21, 2024 (the "Merger Agreement"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation ("Parent") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the "Effective Time"), each restricted stock unit (each, an "RSU") granted by the Issuer that was outstanding and unvested immediately prior to the Effective Time was converted into the right to receive (i) an amount of cash equal to the product of (A) the number of shares of common stock then underlying such RSU multiplied by (B) $5.50 in cash, without interest (such amount, the "Closing Cash Consideration") and (ii) contingent value rights ("CVRs") in an amount equal to the total number of shares of common stock then underlying such RSUs. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of June 21, 2024 (the "Merger Agreement"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation ("Parent") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the "Effective Time"), each restricted stock unit (each, an "RSU") granted by the Issuer that was outstanding and unvested immediately prior to the Effective Time was converted into the right to receive (i) an amount of cash equal to the product of (A) the number of shares of common stock then underlying such RSU multiplied by (B) $5.50 in cash, without interest (such amount, the "Closing Cash Consideration") and (ii) contingent value rights ("CVRs") in an amount equal to the total number of shares of common stock then underlying such RSUs. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of June 21, 2024 (the "Merger Agreement"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation ("Parent") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the "Effective Time"), each restricted stock unit (each, an "RSU") granted by the Issuer that was outstanding and unvested immediately prior to the Effective Time was converted into the right to receive (i) an amount of cash equal to the product of (A) the number of shares of common stock then underlying such RSU multiplied by (B) $5.50 in cash, without interest (such amount, the "Closing Cash Consideration") and (ii) contingent value rights ("CVRs") in an amount equal to the total number of shares of common stock then underlying such RSUs. F1 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of June 21, 2024 (the "Merger Agreement"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation ("Parent") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the "Effective Time"), each restricted stock unit (each, an "RSU") granted by the Issuer that was outstanding and unvested immediately prior to the Effective Time was converted into the right to receive (i) an amount of cash equal to the product of (A) the number of shares of common stock then underlying such RSU multiplied by (B) $5.50 in cash, without interest (such amount, the "Closing Cash Consideration") and (ii) contingent value rights ("CVRs") in an amount equal to the total number of shares of common stock then underlying such RSUs. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 21:22 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GrantPerformance-Based Restricted Stock Units · Derivative | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-034103 · tm248828-4_4seq1.xml · derivative · entry 2 Wood Todd Michael · CIK 0001739840 · President of U.S. Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Performance-Based Restricted Stock Unit (PSU) represents a contingent right to receive one (1) share of the common stock of the Issuer, subject to the achievement of applicable performance criteria. F4 · derivative.exercise_date: The PSUs were awarded to the Reporting Person under the Alimera Sciences, Inc. 2024 Equity Inducement Plan. Each PSU represents the right to receive, following vesting, one (1) share of common stock of the Issuer. 1/3 of the PSUs will vest for each performance year during the 3-year performance period beginning January 1, 2024 and ending on December 31, 2026 if either one of the pre-established annual revenue target and stock price target is satisfied during such performance year, as set forth in the Reporting Person's award agreement. The number of PSUs reported reflects the maximum number of PSUs that the Reporting Person may earn at the end of the 3-year performance period. F4 · derivative.expiration_date: The PSUs were awarded to the Reporting Person under the Alimera Sciences, Inc. 2024 Equity Inducement Plan. Each PSU represents the right to receive, following vesting, one (1) share of common stock of the Issuer. 1/3 of the PSUs will vest for each performance year during the 3-year performance period beginning January 1, 2024 and ending on December 31, 2026 if either one of the pre-established annual revenue target and stock price target is satisfied during such performance year, as set forth in the Reporting Person's award agreement. The number of PSUs reported reflects the maximum number of PSUs that the Reporting Person may earn at the end of the 3-year performance period. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 21:22 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GrantRestricted Stock Units · Derivative | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-034103 · tm248828-4_4seq1.xml · derivative · entry 1 Wood Todd Michael · CIK 0001739840 · President of U.S. Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one (1) share of the common stock of the Issuer. F3 · derivative.exercise_date: The RSUs were awarded to the Reporting Person under the Alimera Sciences, Inc. 2024 Equity Inducement Plan. 25% of the RSUs are scheduled to vest on the first anniversary of the Reporting Person's employment commencement date and the remaining portion of the RSUs will vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous employment with the Issuer on each such vesting date. F3 · derivative.expiration_date: The RSUs were awarded to the Reporting Person under the Alimera Sciences, Inc. 2024 Equity Inducement Plan. 25% of the RSUs are scheduled to vest on the first anniversary of the Reporting Person's employment commencement date and the remaining portion of the RSUs will vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous employment with the Issuer on each such vesting date. Read SEC document |
| December 11, 2023 Filed Dec 13, 2023 17:20 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GrantEmployee Stock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001104659-23-125783 · tm2332858-2_4seq1.xml · derivative · entry 1 Wood Todd Michael · CIK 0001739840 · President of U.S. Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2027-12-11 F1 · derivative.exercise_date: The employee stock option shall vest as follows: one-fourth of the shares shall vest on December 11, 2024, with the remaining shares vesting in 36 equal monthly installments beginning on January 11, 2025, subject to reporting person's continuous employment. Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 20:17 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 350 | $2.85 | $997.50 |
DisclosureSEC source: 0001209191-23-037207 · doc4.xml · nonDerivative · entry 1 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 284,757 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on June 24, 2020. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 18:52 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 2,549 | $2.53 | $6,448.97 |
DisclosureSEC source: 0001209191-23-036042 · doc4.xml · nonDerivative · entry 3 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,107 F3 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on March 7, 2023. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 18:52 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 2,254 | $2.53 | $5,702.62 |
DisclosureSEC source: 0001209191-23-036042 · doc4.xml · nonDerivative · entry 2 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 287,656 F2 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on March 23, 2022. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 18:52 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 189 | $2.53 | $478.17 |
DisclosureSEC source: 0001209191-23-036042 · doc4.xml · nonDerivative · entry 1 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 289,910 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on March 29, 2021. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 20:03 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 412 | $3.26 | $1,343.12 |
DisclosureSEC source: 0001209191-23-019070 · doc4.xml · nonDerivative · entry 1 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,099 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on June 24, 2020. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 20:07 UTC | DermTech, Inc. DMTK · Entity 89998 | GrantCommon Stock | 85,114 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-017691 · doc4.xml · nonDerivative · entry 3 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,511 F3 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. Subject to the reporting person's continued service, (i) three thirty-sixths (3/36) of the restricted stock units shall vest on June 5, 2023 and (ii) the remaining thirty-three thirty-sixths (33/36) shall vest in eleven (11) equal installments of three thirty-sixths (3/36) on the fifth day of each third month following June 5, 2023 until the final vesting date on March 5, 2026. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 20:07 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 8,512 | $4.06 | $34,558.72 |
DisclosureSEC source: 0001209191-23-017691 · doc4.xml · nonDerivative · entry 2 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,397 F2 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on March 23, 2022. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 20:07 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 201 | $4.06 | $816.06 |
DisclosureSEC source: 0001209191-23-017691 · doc4.xml · nonDerivative · entry 1 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,909 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on March 29, 2021. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 20:00 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 356 | $2.22 | $790.32 |
DisclosureSEC source: 0001209191-22-061319 · doc4.xml · nonDerivative · entry 1 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,110 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on June 24, 2020. Read SEC document |
| December 08, 2022 Filed Dec 8, 2022 20:01 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 448 | $2.32 | $1,039.36 |
DisclosureSEC source: 0001209191-22-060423 · doc4.xml · nonDerivative · entry 2 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,466 F2 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on January 17, 2020. Read SEC document |
| December 06, 2022 Filed Dec 8, 2022 20:01 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 185 | $2.44 | $451.40 |
DisclosureSEC source: 0001209191-22-060423 · doc4.xml · nonDerivative · entry 1 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,914 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on March 29, 2021. Read SEC document |
| September 12, 2022 Filed Sep 14, 2022 20:03 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 350 | $5.99 | $2,096.50 |
DisclosureSEC source: 0001209191-22-049995 · doc4.xml · nonDerivative · entry 1 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,099 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on June 24, 2020. Read SEC document |
| September 08, 2022 Filed Sep 8, 2022 20:08 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 434 | $5.65 | $2,452.10 |
DisclosureSEC source: 0001209191-22-049240 · doc4.xml · nonDerivative · entry 2 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,449 F2 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on January 17, 2020. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:08 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 181 | $5.43 | $982.83 |
DisclosureSEC source: 0001209191-22-049240 · doc4.xml · nonDerivative · entry 1 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,883 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on March 29, 2021. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 20:09 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 375 | $4.81 | $1,803.75 |
DisclosureSEC source: 0001209191-22-037163 · doc4.xml · nonDerivative · entry 1 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,064 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on June 24, 2020. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 20:04 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 433 | $6.26 | $2,710.58 |
DisclosureSEC source: 0001209191-22-035242 · doc4.xml · nonDerivative · entry 2 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,439 F2 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on January 17, 2020. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 20:04 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 180 | $6.48 | $1,166.40 |
DisclosureSEC source: 0001209191-22-035242 · doc4.xml · nonDerivative · entry 1 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,872 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on March 29, 2021. Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 20:15 UTC | DermTech, Inc. DMTK · Entity 89998 | GrantCommon Stock | 75,215 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021194 · doc4.xml · nonDerivative · entry 1 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,052 F1 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. Subject to the reporting person's continued service, (i) twelve thirty-sixths (12/36) of the restricted stock units shall vest on March 5, 2023 and (ii) the remaining twenty-four thirty-sixths (24/36) shall vest in eight (8) equal installments of three thirty-sixths (3/36) on the fifth day of each third month following March 5, 2023 until the final vesting date on March 5, 2025. Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 20:16 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 348 | $14.55 | $5,063.40 |
DisclosureSEC source: 0001209191-22-019002 · doc4.xml · nonDerivative · entry 1 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,837 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on June 24, 2020. Read SEC document |
| March 08, 2022 Filed Mar 9, 2022 20:08 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 419 | $12.64 | $5,296.16 |
DisclosureSEC source: 0001209191-22-017716 · doc4.xml · nonDerivative · entry 2 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,185 F2 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on January 17, 2020. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 20:08 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 698 | $13.03 | $9,094.94 |
DisclosureSEC source: 0001209191-22-017716 · doc4.xml · nonDerivative · entry 1 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,604 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on March 29, 2021. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 06:14 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 637 | $16.29 | $10,376.73 |
DisclosureSEC source: 0001209191-21-069871 · doc4.xml · nonDerivative · entry 3 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,302 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12,2021. Read SEC document |
| December 13, 2021 Filed Dec 16, 2021 06:14 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 794 | $16.71 | $13,267.74 |
DisclosureSEC source: 0001209191-21-069871 · doc4.xml · nonDerivative · entry 2 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,939 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12,2021. Read SEC document |
| December 13, 2021 Filed Dec 16, 2021 06:14 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 360 | $16.71 | $6,015.60 |
DisclosureSEC source: 0001209191-21-069871 · doc4.xml · nonDerivative · entry 1 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,733 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on June 24, 2020. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 20:06 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 426 | $18.46 | $7,863.96 |
DisclosureSEC source: 0001209191-21-069140 · doc4.xml · nonDerivative · entry 1 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,093 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on January 17, 2020. Read SEC document |
| September 14, 2021 Filed Sep 15, 2021 20:34 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 649 | $35.06 | $22,753.94 |
DisclosureSEC source: 0001209191-21-056273 · doc4.xml · nonDerivative · entry 3 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,519 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12,2021. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:34 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 778 | $36.19 | $28,155.82 |
DisclosureSEC source: 0001209191-21-056273 · doc4.xml · nonDerivative · entry 2 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,168 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12,2021. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:34 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 348 | $36.19 | $12,594.12 |
DisclosureSEC source: 0001209191-21-056273 · doc4.xml · nonDerivative · entry 1 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,946 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on June 24, 2020. Read SEC document |
| September 08, 2021 Filed Sep 10, 2021 20:16 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 442 | $36.18 | $15,991.56 |
DisclosureSEC source: 0001209191-21-055585 · doc4.xml · nonDerivative · entry 1 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,294 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on January 17, 2020. Read SEC document |
| June 14, 2021 Filed Jun 15, 2021 20:13 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 901 | $41.84 | $37,694.69 |
DisclosureSEC source: 0001209191-21-040770 · doc4.xml · nonDerivative · entry 4 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,736 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12,2021. F5 · price: This transaction was executed in multiple trades at prices ranging from $41.65 to $41.99, inclusive. The reported price reflects the weighted average sale price. F6 · price: The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (5) of this Form 4. Read SEC document |
| June 14, 2021 Filed Jun 15, 2021 20:13 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 1,689 | $41.22 | $69,627.00 |
DisclosureSEC source: 0001209191-21-040770 · doc4.xml · nonDerivative · entry 3 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,637 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12,2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $40.65 to $41.64, inclusive. The reported price reflects the weighted average sale price. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 20:13 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 795 | $41.37 | $32,891.14 |
DisclosureSEC source: 0001209191-21-040770 · doc4.xml · nonDerivative · entry 2 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,326 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12,2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $41.30 to $41.42, inclusive. The reported price reflects the weighted average sale price. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 20:13 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 1,398 | $41.08 | $57,433.34 |
DisclosureSEC source: 0001209191-21-040770 · doc4.xml · nonDerivative · entry 1 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,121 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on June 24, 2020. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 20:19 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 425 | $43.43 | $18,457.75 |
DisclosureSEC source: 0001209191-21-039693 · doc4.xml · nonDerivative · entry 1 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,519 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on January 17, 2020. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:08 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 10,000 | $40.00 | $400,000.00 |
DisclosureSEC source: 0001209191-21-036364 · doc4.xml · nonDerivative · entry 1 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,944 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2021. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 17:01 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 488 | $47.80 | $23,326.01 |
DisclosureSEC source: 0001209191-21-026675 · doc4.xml · nonDerivative · entry 3 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,944 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $47.51 to $48.00, inclusive. The reported price reflects the weighted-average sale price. F5 · price: The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (4) of this Form 4. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 17:01 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 3,919 | $46.73 | $183,133.30 |
DisclosureSEC source: 0001209191-21-026675 · doc4.xml · nonDerivative · entry 2 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,432 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $46.385 to $47.15, inclusive. The reported price reflects the weighted-average sale price. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 17:01 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 5,593 | $45.93 | $256,861.88 |
DisclosureSEC source: 0001209191-21-026675 · doc4.xml · nonDerivative · entry 1 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,351 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $45.37 to $46.36, inclusive. The reported price reflects the weighted-average sale price. Read SEC document |
| March 29, 2021 Filed Mar 31, 2021 16:56 UTC | DermTech, Inc. DMTK · Entity 89998 | GrantStock Option (right to buy) · Derivative | 12,148 | $0.00 Strike: $44.48 | $0.00 |
DisclosureSEC source: 0001209191-21-023797 · doc4.xml · derivative · entry 2 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,148 Underlying: Common Stock · 12,148 shares Expires 2031-03-29 F2 · derivative.exercise_date: Subject to the reporting person's continued service, (i) twelve forty-eighths (12/48) of the shares of issuer common stock exercisable pursuant to this option shall vest on March 29, 2022 and (ii) the remaining thirty-six forty-eighths (36/48) shall vest in thirty-six (36) equal monthly installments of one forty-eighth (1/48) on the twenty-ninth day of each month following March 29, 2022 until the final vesting date on March 29, 2025. Read SEC document |
| March 29, 2021 Filed Mar 31, 2021 16:56 UTC | DermTech, Inc. DMTK · Entity 89998 | GrantCommon Stock | 8,162 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-023797 · doc4.xml · nonDerivative · entry 1 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,994 F1 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. Subject to the reporting person's continued service, (i) twelve forty-eighths (12/48) of the restricted stock units shall vest on March 5, 2022 and (ii) the remaining thirty-six forty-eighths (36/48) shall vest in twelve (12) equal installments of three forty-eighths (3/48) on the fifth day of each third month following March 5, 2022 until the final vesting date on March 5, 2025. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 17:18 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 417 | $50.04 | $20,866.68 |
DisclosureSEC source: 0001209191-21-019543 · doc4.xml · nonDerivative · entry 1 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,782 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on January 17, 2020. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 16:10 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 428 | $11.86 | $5,076.08 |
DisclosureSEC source: 0001209191-20-062701 · doc4.xml · nonDerivative · entry 1 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,199 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on January 17, 2020. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 19:38 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 495 | $11.25 | $5,569.00 |
DisclosureSEC source: 0001209191-20-050343 · doc4.xml · nonDerivative · entry 2 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,627 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on January 17, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $10.90 to $11.89, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 19:38 UTC | DermTech, Inc. DMTK · Entity 89998 | SaleCommon Stock | 850 | $10.57 | $8,988.67 |
DisclosureSEC source: 0001209191-20-050343 · doc4.xml · nonDerivative · entry 1 Wood Todd Michael · CIK 0001739840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,122 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on January 17, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $10.20 to $10.895, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.